Back to Journals » Vascular Health and Risk Management » Volume 9
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension
Authors Billecke SS, Marcovitz PA
Received 30 November 2012
Accepted for publication 24 December 2012
Published 16 March 2013 Volume 2013:9 Pages 95—104
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Scott S Billecke, Pamela A Marcovitz
Beaumont Health System, Ministrelli Women’s Heart Center, Royal Oak, MI, USA
Abstract: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.
Keywords: Angiotensin receptor blocker, antihypertensive, calcium channel blocker, clinical trial, combination pill
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.